New York, May 26, 2026, 09:06 EDT
- Cyclerion ended Friday at $3.18, up 0.6%. U.S. markets were set to close for Memorial Day.
- The key mover here is the company’s planned all-stock merger with Korsana Biosciences. The deal is set to close in the third quarter, pending approvals.
- Cyclerion shareholders look set to get roughly 1.5% of the new company. The rest, about 98.5%, would go to Korsana holders and backers in the financing.
Cyclerion Therapeutics shares will trade on Nasdaq Tuesday with investors watching developments around its planned merger with Korsana Biosciences. There was no new company announcement. The stock finished Friday at $3.18, up 0.6%. Regular Nasdaq trading is set to start at 9:30 a.m. Eastern after Monday’s Memorial Day holiday.
Korsana’s Alzheimer’s drug deal has turned Cyclerion into a backdoor public listing for the program. At Friday’s price, with 4.33 million shares showing in the recent quarterly, Cyclerion’s equity sits near $14 million. That leaves the company with limited cushion as it faces deal conditions like regulatory OKs, funding, and keeping its Nasdaq spot.
Nasdaq edges up, biotech soft ahead of holiday
The market stayed firm going into the long weekend, but biotech was weaker. The Nasdaq Composite added 0.2% to 26,343.97 Friday. The Nasdaq Biotechnology Index lost 0.17% to 5,891.46.
Cyclerion and Korsana, a private firm, said April 1 they’ll merge in an all-stock deal. The merged business will take the name Korsana Biosciences and list on Nasdaq as KRSA. Korsana’s lead candidate, KRSA-028, targets Alzheimer’s.
Korsana has secured about $380 million in PIPE financing. The companies said the private investment is set to close just ahead of the merger and should fund the combined group into 2029. That cash runway is supposed to cover KRSA-028 through Phase 1 healthy-volunteer data around mid-2027 and interim proof-of-concept amyloid plaque clearance results in Alzheimer’s patients by year-end 2027.
Cyclerion shareholders will likely have about 1.5% of the merged company when the deal wraps up, while pre-merger Korsana holders and backers in the pre-closing financing are set to own around 98.5%. Cyclerion president and CEO Regina Graul said the merger is “the best path forward.” Korsana CEO Jonathan Violin said “patients deserve better options” in neurodegenerative disease. Business Wire
Korsana is moving into the Alzheimer’s market, where Eisai and Biogen already have Leqembi, and Eli Lilly’s Kisunla is also out. Both drugs use amyloid-beta antibodies. Amyloid beta forms plaques in Alzheimer’s brains. The FDA gave Leqembi full approval in 2023 and cleared Kisunla in 2024.
Korsana says KRSA-028 is a new “shuttled” antibody meant to get into the brain better and cut the risk of amyloid-related imaging abnormalities, or ARIA—swelling or bleeding that can show up on scans after anti-amyloid drugs. This is their current claim for the drug, which hasn’t been approved. Business Wire
Cyclerion’s CYC-126 program targets treatment-resistant depression, or cases where patients haven’t responded to standard options. The company said in February it got positive pre-IND written feedback from the FDA—an IND is required to start U.S. clinical tests. Cyclerion said it’s still aiming to begin a Phase 2 proof-of-concept trial in the second half of 2026.
Cyclerion’s latest filing points to a slim cushion. For the March quarter, the company booked no revenue, posted a net loss of $3.18 million, and held around $2.8 million in unrestricted cash and cash equivalents as of March 31. Cyclerion said that’s enough to fund operations into the third quarter of 2026.
The risk is still there. Cyclerion said there is “substantial doubt” about its ability to keep operating as a going concern. That is accounting language for the company possibly lacking enough cash to run for another year. The planned merger isn’t done yet. It still needs shareholder signoff, a declared-effective SEC registration, funding to come through, and Nasdaq’s OK. The company also flagged that its contingent value rights (CVRs), tied to possible payouts from legacy assets, might never pay out. SEC
Looking to next week, the stock’s action will probably depend less on how it closed Friday and more on any news about the merger steps—proxy documents, when shareholders will vote, financing, and what’s happening with the Nasdaq listing. With a micro-cap and a deal of this scale, even no news can move the shares.
